Merck & Co., Inc. Financial Highlights Package First Quarter 2025 Table of Contents Table 1: GAAP P&L ..........................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter ...... 2 Table 2a: GAAP to Non-GAAP Reconciliation 1Q25 ........................... 3 Table 2b: GAAP to Non-GAAP Reconciliation 1Q24 ........................... 4 Table 3: Sales – Current Year and Prior Year by Quarter ................ 5 Table 3a: Sales – U.S. / International 1Q25 ............................................6 Table 3b: Sales – Pharmaceutical Geographic Split .......................... 7 Table 4: Other (Income) Expense..................................................... 8 -- 1 of 9 -- Sales 15,529 $ 15,775 $ -2% Costs, Expenses and Other Cost of sales 3,419 3,540 -3% Selling, general and administrative 2,552 2,483 3% Research and development 3,621 3,992 -9% Restructuring costs 69 123 -44% Other (income) expense, net (35) (33) 6% Income Before Taxes 5,903 5,670 4% Income Tax Provision 818 903 Net Income 5,085 4,767 7% Less: Net Income Attributable to Noncontrolling Interests 6 5 Net Income Attributable to Merck & Co., Inc. 5,079 $ 4,762 $ 7% Earnings per Common Share Assuming Dilution 2.01 $ 1.87 $ 7% Average Shares Outstanding Assuming Dilution 2,531 2,544 Tax Rate 13.9% 15.9% MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change 1Q25 1Q24 1 -- 2 of 9 -- Sales 15,529 $ 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 $ -2% Costs, Expenses and Other Cost of sales 3,419 3,540 3,745 4,080 3,828 15,193 -3% Selling, general and administrative 2,552 2,483 2,739 2,731 2,864 10,816 3% Research and development 3,621 3,992 3,500 5,862 4,585 17,938 -9% Restructuring costs 69 123 80 56 51 309 -44% Other (income) expense, net (35) (33) 42 (162) 126 (24) 6% Income Before Taxes 5,903 5,670 6,006 4,090 4,170 19,936 4% Income Tax Provision 818 903 545 929 425 2,803 Net Income 5,085 4,767 5,461 3,161 3,745 17,133 7% Less: Net Income Attributable to Noncontrolling Interests 6 5 6 4 2 16 Net Income Attributable to Merck & Co., Inc. 5,079 $ 4,762 $ 5,455 $ 3,157 $ 3,743 $ 17,117 $ 7% Earnings per Common Share Assuming Dilution 2.01 $ 1.87 $ 2.14 $ 1.24 $ 1.48 $ 6.74 $ 7% Average Shares Outstanding Assuming Dilution 2,531 2,544 2,544 2,541 2,537 2,541 Tax Rate 13.9% 15.9% 9.1% 22.7% 10.2% 14.1% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 4Q 1Q Full Year 2025 1Q 1Q 2Q 3Q 2024 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2 -- 3 of 9 -- First Quarter Cost of sales 3,419 $ 620 36 656 2,763 $ Selling, general and administrative 2,552 23 23 2,529 Research and development 3,621 7 7 3,614 Restructuring costs 69 69 69 – Other (income) expense, net (35) (3) (107) (110) 75 Income Before Taxes 5,903 (647) (105) 107 (645) 6,548 Income Tax Provision (Benefit) 818 (117) (3) (18) (3) 22 (3) (113) 931 Net Income 5,085 (530) (87) 85 (532) 5,617 Net Income Attributable to Merck & Co., Inc. 5,079 (530) (87) 85 (532) 5,611 Earnings per Common Share Assuming Dilution 2.01 $ (0.21) (0.03) 0.03 (0.21) 2.22 $ Tax Rate 13.9% 14.2% Only the line items that are affected by non-GAAP adjustments are shown. The company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. MERCK & CO., INC. FIRST QUARTER 2025 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a GAAP Acquisition- and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal Non-GAAP 3 -- 4 of 9 -- First Quarter Cost of sales 3,540 $ 463 116 579 2,961 $ Selling, general and administrative 2,483 21 5 26 2,457 Research and development 3,992 16 2 18 3,974 Restructuring costs 123 123 123 – Other (income) expense, net (33) (4) (116) (120) 87 Income Before Taxes 5,670 (496) (246) 116 (626) 6,296 Income Tax Provision (Benefit) 903 (92) (3) (42) (3) 25 (3) (109) 1,012 Net Income 4,767 (404) (204) 91 (517) 5,284 Net Income Attributable to Merck & Co., Inc. 4,762 (404) (204) 91 (517) 5,279 Earnings per Common Share Assuming Dilution 1.87 $ (0.16) (0.08) 0.04 (0.20) 2.07 $ Tax Rate 15.9% 16.1% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. FIRST QUARTER 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition- and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2b (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP The company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non- GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. 4 -- 5 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2025 2024 1Q 1Q 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % TOTAL SALES (1) $15,529 $15,775 $16,112 $16,657 $15,624 $64,168 -2 1 PHARMACEUTICAL 13,638 14,006 14,408 14,943 14,042 57,400 -3 -1 Oncology Keytruda 7,205 6,947 7,270 7,429 7,836 29,482 4 6 Alliance Revenue – Lynparza (2) 312 292 317 337 365 1,311 7 8 Alliance Revenue – Lenvima (2) 258 255 249 251 255 1,010 1 2 Welireg 137 85 126 139 160 509 62 63 Alliance Revenue – Reblozyl (3) 119 71 90 100 110 371 68 68 Vaccines (4) Gardasil/Gardasil 9 1,327 2,249 2,478 2,306 1,550 8,583 -41 -40 ProQuad/M-M-R II/Varivax 539 570 617 703 594 2,485 -5 -5 Vaxneuvance 230 219 189 239 161 808 5 7 RotaTeq 228 216 163 193 139 711 5 7 Capvaxive 107 47 50 97 - - Pneumovax 23 41 61 59 68 74 263 -33 -30 Hospital Acute Care Bridion 441 440 455 420 449 1,764 - 1 Prevymis 208 174 188 208 215 785 19 22 Dificid 83 73 92 96 79 340 13 13 Zerbaxa 70 56 62 64 70 252 24 27 Cardiovascular Winrevair 280 70 149 200 419 - - Alliance Revenue - Adempas/Verquvo (5) 106 98 106 102 109 415 8 8 Adempas (6) 68 70 72 72 73 287 -3 1 Virology Lagevrio 102 350 110 383 121 964 -71 -69 Isentress/Isentress HD 90 111 89 102 92 394 -19 -17 Delstrigo 67 56 60 65 69 249 19 24 Pifeltro 45 42 39 42 40 163 7 7 Neuroscience Belsomra 50 46 53 78 45 222 8 13 Immunology Simponi 184 172 189 543 -100 -100 Remicade 39 35 41 114 -100 -100 Diabetes (7) Januvia 549 419 405 278 232 1,334 31 33 Janumet 247 251 224 204 255 935 -2 2 Other Pharmaceutical (8) 729 632 618 638 699 2,590 16 18 ANIMAL HEALTH 1,588 1,511 1,482 1,487 1,397 5,877 5 10 Livestock 924 850 837 886 889 3,462 9 16 Companion Animal 664 661 645 601 508 2,415 - 3 Other Revenues (9) 303 258 222 227 185 891 17 16 Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $876 million in the first quarter of 2025 and $745 million in the first quarter of 2024. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $95 million in the first quarter of 2025 and $61 million in the first quarter of 2024. (1) Only select products are shown. (2) Alliance Revenue represents the company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,607 million in the first quarter of 2025 and $3,424 million in the first quarter of 2024. (5) Alliance Revenue represents the company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in the company's marketing territories. 5 -- 6 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FIRST QUARTER 2025 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 1Q 2025 1Q 2024 % Change 1Q 2025 1Q 2024 % Change 1Q 2025 1Q 2024 % Change TOTAL SALES (1) $15,529 $15,775 -2 $8,522 $7,478 14 $7,007 $8,297 -16 PHARMACEUTICAL 13,638 14,006 -3 7,927 6,936 14 5,711 7,070 -19 Oncology Keytruda 7,205 6,947 4 4,308 4,119 5 2,897 2,828 2 Alliance Revenue – Lynparza (2) 312 292 7 145 135 7 168 157 7 Alliance Revenue – Lenvima (2) 258 255 1 186 173 8 72 82 -12 Welireg 137 85 62 123 77 59 15 7 98 Alliance Revenue – Reblozyl (3) 119 71 68 101 58 72 18 12 47 Vaccines (4) Gardasil/Gardasil 9 1,327 2,249 -41 536 488 10 790 1,761 -55 ProQuad/M-M-R II/Varivax 539 570 -5 423 438 -3 116 133 -12 Vaxneuvance 230 219 5 139 161 -14 92 58 59 RotaTeq 228 216 5 164 149 10 64 67 -4 Capvaxive 107 - 106 - 1 - Pneumovax 23 41 61 -33 -2 6 -126 42 55 -23 Hospital Acute Care Bridion 441 440 - 378 329 15 63 111 -43 Prevymis 208 174 19 102 74 37 106 100 6 Dificid 83 73 13 72 68 6 11 5 117 Zerbaxa 70 56 24 42 33 27 28 23 20 Cardiovascular Winrevair 280 - 268 - 12 - Alliance Revenue - Adempas/Verquvo (5) 106 98 8 97 90 8 9 8 12 Adempas (6) 68 70 -3 68 70 -3 Virology Lagevrio 102 350 -71 35 45 -21 67 305 -78 Isentress/Isentress HD 90 111 -19 51 50 2 39 61 -35 Delstrigo 67 56 19 15 12 28 52 44 17 Pifeltro 45 42 7 32 29 8 13 13 2 Neuroscience Belsomra 50 46 8 13 15 -10 37 32 16 Immunology Simponi 184 -100 184 -100 Remicade 39 -100 39 -100 Diabetes (7) Januvia 549 419 31 344 183 88 204 236 -13 Janumet 247 251 -2 65 39 68 182 212 -14 Other Pharmaceutical (8) 729 632 16 184 165 12 545 467 17 ANIMAL HEALTH 1,588 1,511 5 502 474 6 1,086 1,037 5 Livestock 924 850 9 194 166 17 730 683 7 Companion Animal 664 661 - 308 308 - 356 354 1 Other Revenues (9) 303 258 17 93 68 37 210 190 11 (6) Net product sales in the company's marketing territories. (7) Total Diabetes sales were $876 million and $745 million on a global basis in the first quarter of 2025 and 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $95 million in the first quarter of 2025 and $61 million in the first quarter of 2024. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,607 million and $3,424 million on a global basis in the first quarter of 2025 and 2024, respectively. (5) Alliance Revenue represents the company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 9 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b 2025 2024 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q TOTAL PHARMACEUTICAL $13,638 $14,006 $14,408 $14,943 $14,042 $57,400 -3 United States 7,927 6,936 7,399 8,227 7,728 30,290 14 % Pharmaceutical Sales 58.1% 49.5% 51.4% 55.1% 55.0% 52.8% Europe (1) 2,384 2,555 2,572 2,620 2,498 10,246 -7 % Pharmaceutical Sales 17.5% 18.2% 17.9% 17.5% 17.8% 17.9% China (2) 668 1,744 1,790 996 864 5,394 -62 % Pharmaceutical Sales 4.9% 12.5% 12.4% 6.7% 6.2% 9.4% Japan 651 802 664 919 813 3,199 -19 % Pharmaceutical Sales 4.8% 5.7% 4.6% 6.2% 5.8% 5.6% Latin America 589 601 661 730 680 2,672 -2 % Pharmaceutical Sales 4.3% 4.3% 4.6% 4.9% 4.8% 4.7% Asia Pacific (other than China and Japan) 535 580 595 669 612 2,457 -8 % Pharmaceutical Sales 3.9% 4.1% 4.1% 4.5% 4.4% 4.3% Eastern Europe/Middle East/Africa 435 395 353 400 348 1,495 10 % Pharmaceutical Sales 3.2% 2.8% 2.4% 2.7% 2.5% 2.6% Canada 125 138 143 133 144 558 -9 % Pharmaceutical Sales 0.9% 1.0% 1.0% 0.9% 1.0% 1.0% Other 324 255 231 249 355 1,089 27 % Pharmaceutical Sales 2.4% 1.9% 1.6% 1.5% 2.5% 1.7% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. (2) Gardasil/Gardasil 9 sales in China were $193 million in the first quarter of 2025 and $1,253 million, $1,312 million, $517 million and $446 million in the first, second, third and fourth quarter of 2024, respectively. 7 -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 1Q25 1Q24 Interest income (109) $ (73) $ Interest expense 313 303 Exchange losses 90 83 Income from investments in equity securities, net (1) (90) (143) Net periodic defined benefit plan (credit) cost other than service cost (148) (160) Other, net (91) (43) Total (35) $ (33) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 8 -- 9 of 9 --